Home › Funds › Bracebridge Capital, LLC › RNA

Bracebridge Capital, LLC position in RNA

ATRIUM THERAPEUTICS INC · Health Care

Bracebridge Capital, LLC reported holding 524,477 shares of RNA (ATRIUM THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$4.3M, representing 0.84% of its reported portfolio and ranking #11 among its reported holdings. Bracebridge Capital, LLC has disclosed RNA holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

Latest position (Q3 2026)524.48K sh
Reported value held$4.34M
Portfolio Weight0.84%
First reportedQ1 2026
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Bracebridge Capital, LLC's RNA position evolved

Bracebridge Capital, LLC first disclosed a stake in RNA in Q1 2026 at 139,239 shares (US$1.9M). The position peaked in Q3 2026 at 524,477 shares, worth US$4.3M. Across 3 filings, Bracebridge Capital, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 524,477 shares valued at US$4.3M — an increase of 385,238 shares quarter over quarter.. Notable position changes include a 277% increase in Q3 2026 (shares fell 9% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2026 139.24K $1.86M New
Q2 2026 139.24K $1.87M Hold
Q3 2026 524.48K $4.34M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RNA and 13F data

RNA (ATRIUM THERAPEUTICS INC) is a Health Care company. 88 other funds we track also report a position in RNA — the largest reported positions include Sessa Capital IM, L.P. (US$20.2M), TIG Advisors, LLC (US$7.6M), O'Connor Alternative Investments LLC (US$4.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RNA

All RNA fund holders →

FAQ

How long has Bracebridge Capital, LLC held RNA?

Bracebridge Capital, LLC has disclosed RNA holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

What is Bracebridge Capital, LLC's current position in RNA?

As of Q3 2026, Bracebridge Capital, LLC holds 524.48K shares of RNA (ATRIUM THERAPEUTICS INC), valued at $4.34M, representing 0.84% of its reported portfolio and ranking #11.

Has Bracebridge Capital, LLC been buying or selling RNA?

In the latest 13F filing (Q3 2026), Bracebridge Capital, LLC increased its position in RNA. The position peaked in Q3 2026 at 524.48K shares.

Which other funds hold RNA?

Other major institutional holders of RNA include Sessa Capital IM, L.P., TIG Advisors, LLC, O'Connor Alternative Investments LLC, among 88 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.